NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.54
(5.26%)
USD 0.54
(5.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -390 Thousand USD | 88.26% |
| 2022 | -3.32 Million USD | 52.24% |
| 2021 | -6.95 Million USD | 39.27% |
| 2020 | -11.44 Million USD | -296.02% |
| 2019 | -2.89 Million USD | 9.17% |
| 2018 | -3.18 Million USD | 0.5% |
| 2017 | -3.19 Million USD | 66.37% |
| 2016 | -9.51 Million USD | -1203.01% |
| 2015 | -730 Thousand USD | 86.55% |
| 2014 | -5.42 Million USD | 48.3% |
| 2013 | -10.5 Million USD | 17.55% |
| 2012 | -12.73 Million USD | -51.1% |
| 2011 | -8.42 Million USD | 26.25% |
| 2010 | -11.42 Million USD | -8.68% |
| 2009 | -10.51 Million USD | 6.23% |
| 2008 | -11.21 Million USD | -10.6% |
| 2007 | -10.13 Million USD | -106.79% |
| 2006 | -4.9 Million USD | -122.06% |
| 2005 | -2.2 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.25 Million USD | 109.83% |
| 2024 Q1 | 600 Thousand USD | 253.85% |
| 2023 Q1 | -1.76 Million USD | 46.76% |
| 2023 Q3 | -473 Thousand USD | 65.57% |
| 2023 Q2 | -1.37 Million USD | 22.29% |
| 2023 Q4 | -390 Thousand USD | 17.55% |
| 2023 FY | -390 Thousand USD | 88.26% |
| 2022 Q2 | -1.66 Million USD | 48.96% |
| 2022 Q3 | -1.71 Million USD | -2.95% |
| 2022 FY | -3.32 Million USD | 52.24% |
| 2022 Q4 | -3.32 Million USD | -94.21% |
| 2022 Q1 | -3.25 Million USD | 53.2% |
| 2021 Q4 | -6.95 Million USD | 21.27% |
| 2021 FY | -6.95 Million USD | 39.27% |
| 2021 Q1 | -10.1 Million USD | 11.76% |
| 2021 Q2 | -9.99 Million USD | 1.11% |
| 2021 Q3 | -8.83 Million USD | 11.6% |
| 2020 FY | -11.44 Million USD | -296.02% |
| 2020 Q3 | -12.71 Million USD | -73.4% |
| 2020 Q2 | -7.33 Million USD | -215.45% |
| 2020 Q1 | -2.32 Million USD | 19.61% |
| 2020 Q4 | -11.44 Million USD | 9.94% |
| 2019 FY | -2.89 Million USD | 9.17% |
| 2019 Q1 | 336 Thousand USD | 110.56% |
| 2019 Q2 | 1.05 Million USD | 212.5% |
| 2019 Q3 | -4.29 Million USD | -508.57% |
| 2019 Q4 | -2.89 Million USD | 32.61% |
| 2018 Q3 | -5.2 Million USD | 23.8% |
| 2018 FY | -3.18 Million USD | 0.5% |
| 2018 Q4 | -3.18 Million USD | 38.87% |
| 2018 Q2 | -6.83 Million USD | 18.03% |
| 2018 Q1 | -8.33 Million USD | -160.58% |
| 2017 Q3 | -6.07 Million USD | -6.19% |
| 2017 Q4 | -3.19 Million USD | 47.35% |
| 2017 Q2 | -5.72 Million USD | 22.67% |
| 2017 Q1 | -7.39 Million USD | 22.21% |
| 2017 FY | -3.19 Million USD | 66.37% |
| 2016 Q4 | -9.51 Million USD | -0.87% |
| 2016 Q1 | 1.63 Million USD | 323.7% |
| 2016 Q2 | -2.97 Million USD | -281.94% |
| 2016 Q3 | -9.43 Million USD | -217.4% |
| 2016 FY | -9.51 Million USD | -1203.01% |
| 2015 FY | -730 Thousand USD | 86.55% |
| 2015 Q1 | -5.59 Million USD | -3.11% |
| 2015 Q2 | -7.2 Million USD | -28.76% |
| 2015 Q3 | -3.38 Million USD | 53.07% |
| 2015 Q4 | -730 Thousand USD | 78.42% |
| 2014 Q3 | -7.88 Million USD | -1.64% |
| 2014 Q4 | -5.42 Million USD | 31.14% |
| 2014 Q2 | -7.75 Million USD | 24.81% |
| 2014 Q1 | -10.31 Million USD | 1.75% |
| 2014 FY | -5.42 Million USD | 48.3% |
| 2013 Q2 | -6.59 Million USD | 21.38% |
| 2013 Q1 | -8.38 Million USD | 34.14% |
| 2013 Q4 | -10.5 Million USD | -51.43% |
| 2013 FY | -10.5 Million USD | 17.55% |
| 2013 Q3 | -6.93 Million USD | -5.16% |
| 2012 FY | -12.73 Million USD | -51.1% |
| 2012 Q1 | -6.12 Million USD | 27.37% |
| 2012 Q4 | -12.73 Million USD | -76.41% |
| 2012 Q3 | -7.21 Million USD | -55.15% |
| 2012 Q2 | -4.65 Million USD | 23.98% |
| 2011 Q3 | -12.43 Million USD | -55.9% |
| 2011 Q2 | -7.97 Million USD | 32.59% |
| 2011 FY | -8.42 Million USD | 26.25% |
| 2011 Q1 | -11.82 Million USD | -3.49% |
| 2011 Q4 | -8.42 Million USD | 32.2% |
| 2010 Q1 | -12.51 Million USD | -19.05% |
| 2010 Q2 | -10.07 Million USD | 19.53% |
| 2010 Q3 | -9.24 Million USD | 8.2% |
| 2010 Q4 | -11.42 Million USD | -23.59% |
| 2010 FY | -11.42 Million USD | -8.68% |
| 2009 Q2 | -7.31 Million USD | 22.66% |
| 2009 FY | -10.51 Million USD | 6.23% |
| 2009 Q1 | -9.45 Million USD | 15.68% |
| 2009 Q3 | -10.04 Million USD | -37.39% |
| 2009 Q4 | -10.51 Million USD | -4.66% |
| 2008 FY | -11.21 Million USD | -10.6% |
| 2008 Q1 | -10.37 Million USD | -2.36% |
| 2008 Q2 | -8.92 Million USD | 14.02% |
| 2008 Q3 | -10.75 Million USD | -20.58% |
| 2008 Q4 | -11.21 Million USD | -4.23% |
| 2007 Q3 | -146 Thousand USD | 88.67% |
| 2007 Q1 | -3.75 Million USD | 23.52% |
| 2007 FY | -10.13 Million USD | -106.79% |
| 2007 Q4 | -10.13 Million USD | -6844.52% |
| 2007 Q2 | -1.28 Million USD | 65.63% |
| 2006 FY | -4.9 Million USD | -122.06% |
| 2006 Q4 | -4.9 Million USD | 0.0% |
| 2005 FY | -2.2 Million USD | 0.0% |
| 2005 Q4 | -2.2 Million USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 92.112% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 89.777% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 100.365% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 99.477% |
| Azitra, Inc. | -910.04 Thousand USD | 57.145% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 90.798% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 133.268% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 107.519% |
| CEL-SCI Corporation | 9.42 Million USD | 104.137% |
| iBio, Inc. | -9.75 Million USD | 96.0% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 98.8% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 94.546% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | 69.555% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 188.951% |
| NanoViricides, Inc. | -4.79 Million USD | 91.871% |
| Oragenics, Inc. | -3.17 Million USD | 87.7% |
| BiomX Inc. | -772 Thousand USD | 49.482% |
| BiomX Inc. | -772 Thousand USD | 49.482% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 114.734% |
| Palatin Technologies, Inc. | -8.93 Million USD | 95.636% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 102.814% |
| Theriva Biologics, Inc. | -21.02 Million USD | 98.145% |